Publications by authors named "R Delarue"

Claim this Profile
B
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.
Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant, Maya Hacini, Kamel Laribi, Richard Delarue

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial.
Judith Trotman, Pier Luigi Zinzani, Yuqin Song, Richard Delarue, Pil Kim

Curr Med Res Opin· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Morgane Cheminant, Rene-Olivier Casasnovas, Richard Delarue

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira, Richard Delarue

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M Linton, Pamela McKay, Richard Delarue

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis